Procept Biorobotics Corp Stock Performance
| PRCT Stock | USD 97.29 1.98 1.99% |
On a scale of 0 to 100, Procept Biorobotics holds a performance score of 8. The company holds a Beta of 1.31, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Procept Biorobotics will likely underperform. Please check Procept Biorobotics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Procept Biorobotics' historical price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Procept Biorobotics Corp are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental indicators, Procept Biorobotics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.99) | Five Day Return 3.28 | Year To Date Return 134.77 | Ten Year Return 131.97 | All Time Return 131.97 |
1 | Disposition of 900 shares by Desai Antal Rohit of Procept Biorobotics at 76.9578 subject to Rule 16b-3 | 09/05/2024 |
2 | Disposition of 17810 shares by Desai Antal Rohit of Procept Biorobotics at 76.5984 subject to Rule 16b-3 | 09/10/2024 |
3 | Disposition of 4182 shares by Desai Antal Rohit of Procept Biorobotics at 78.6718 subject to Rule 16b-3 | 09/11/2024 |
4 | PROCEPT BioRobotics Corp Stock Price Up 3.12 percent on Sep 12 | 09/12/2024 |
5 | Disposition of 15917 shares by Kevin Waters of Procept Biorobotics at 4.52 subject to Rule 16b-3 | 09/16/2024 |
6 | Acquisition by Desai Antal Rohit of 1376 shares of Procept Biorobotics subject to Rule 16b-3 | 10/04/2024 |
7 | Acquisition by Reza Zadno of 48575 shares of Procept Biorobotics subject to Rule 16b-3 | 10/14/2024 |
8 | Disposition of 25000 shares by Kevin Waters of Procept Biorobotics at 4.56 subject to Rule 16b-3 | 10/15/2024 |
9 | PROCEPT BioRobotics Corp Stock Price Up 3.18 percent on Oct 29 | 10/29/2024 |
10 | PROCEPT BioRobotics Corp Stock Price Up 3.45 percent on Nov 4 | 11/04/2024 |
11 | Disposition of 3769 shares by Desai Antal Rohit of Procept Biorobotics at 98.2909 subject to Rule 16b-3 | 11/06/2024 |
12 | Are You Looking for a Top Momentum Pick Why PROCEPT BioRobotics Corporation is a Great Choice | 11/07/2024 |
13 | Disposition of 4510 shares by Reza Zadno of Procept Biorobotics at 95.5819 subject to Rule 16b-3 | 11/13/2024 |
14 | PROCEPT BioRobotics Corp Shares Down 4.02 percent on Nov 14 | 11/14/2024 |
15 | Disposition of 10509 shares by Reza Zadno of Procept Biorobotics at 92.7386 subject to Rule 16b-3 | 11/15/2024 |
16 | Acquisition by Alaleh Nouri of 1467 shares of Procept Biorobotics at 4.56 subject to Rule 16b-3 | 11/21/2024 |
17 | PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 | 11/26/2024 |
| Begin Period Cash Flow | 225.7 M |
Procept |
Procept Biorobotics Relative Risk vs. Return Landscape
If you would invest 7,506 in Procept Biorobotics Corp on August 31, 2024 and sell it today you would earn a total of 2,223 from holding Procept Biorobotics Corp or generate 29.62% return on investment over 90 days. Procept Biorobotics Corp is currently generating 0.5166% in daily expected returns and assumes 4.8953% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Procept, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Procept Biorobotics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Procept Biorobotics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Procept Biorobotics Corp, and traders can use it to determine the average amount a Procept Biorobotics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1055
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PRCT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.9 actual daily | 43 57% of assets are more volatile |
Expected Return
| 0.52 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Procept Biorobotics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Procept Biorobotics by adding it to a well-diversified portfolio.
Procept Biorobotics Fundamentals Growth
Procept Stock prices reflect investors' perceptions of the future prospects and financial health of Procept Biorobotics, and Procept Biorobotics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Procept Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.38) % | ||||
| Current Valuation | 5.15 B | ||||
| Shares Outstanding | 54.11 M | ||||
| Price To Book | 21.82 X | ||||
| Price To Sales | 26.34 X | ||||
| Revenue | 136.19 M | ||||
| Gross Profit | 37.09 M | ||||
| EBITDA | (98.09 M) | ||||
| Net Income | (105.9 M) | ||||
| Cash And Equivalents | 269.81 M | ||||
| Cash Per Share | 6.05 X | ||||
| Total Debt | 79.2 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 16.01 X | ||||
| Book Value Per Share | 4.63 X | ||||
| Cash Flow From Operations | (108 M) | ||||
| Earnings Per Share | (1.95) X | ||||
| Market Capitalization | 5.26 B | ||||
| Total Asset | 404.72 M | ||||
| Retained Earnings | (454.57 M) | ||||
| Working Capital | 304.64 M | ||||
About Procept Biorobotics Performance
Assessing Procept Biorobotics' fundamental ratios provides investors with valuable insights into Procept Biorobotics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Procept Biorobotics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 222.76 | 299.75 | |
| Return On Tangible Assets | (0.26) | (0.28) | |
| Return On Capital Employed | (0.30) | (0.32) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.38) | (0.36) |
Things to note about Procept Biorobotics Corp performance evaluation
Checking the ongoing alerts about Procept Biorobotics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Procept Biorobotics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Procept Biorobotics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 136.19 M. Net Loss for the year was (105.9 M) with profit before overhead, payroll, taxes, and interest of 37.09 M. | |
| Procept Biorobotics Corp currently holds about 269.81 M in cash with (108 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.05. | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 |
- Analyzing Procept Biorobotics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Procept Biorobotics' stock is overvalued or undervalued compared to its peers.
- Examining Procept Biorobotics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Procept Biorobotics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Procept Biorobotics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Procept Biorobotics' stock. These opinions can provide insight into Procept Biorobotics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Procept Stock Analysis
When running Procept Biorobotics' price analysis, check to measure Procept Biorobotics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Procept Biorobotics is operating at the current time. Most of Procept Biorobotics' value examination focuses on studying past and present price action to predict the probability of Procept Biorobotics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Procept Biorobotics' price. Additionally, you may evaluate how the addition of Procept Biorobotics to your portfolios can decrease your overall portfolio volatility.